Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effects of Zometa (zoledronic acid, 1
mg per week versus 4 mg every four weeks) on the circulating vascular endothelial growth
factor (VEGF) levels in breast cancer patients with bone metastases. Sixty patients will be
randomized into two groups.